Why this UC Berkeley gene therapy spinout is targeting a $100 million IPO


The Emeryville company says it has improved on the traditional way of delivering corrected copies of genes.

Previous 5 Minutes With ... Udit Batra, CEO of MilliporeSigma
Next Alabama health care system hit by ransomware attack